Abstract

BackgroundThe aim of this study was to investigate whether marketed antibiotics package sizes are in accordance with treatment durations recommended in guidelines for prescribing antibiotics in sore throat and urinary tract infections.MethodsNational drug database was searched with limitation to Antibacterials for systemic use. Formulations which did not have pre-specified dosage unit by the manufacturer were excluded (e.g. powders for oral solutions). The final list contained 94 drugs with 23 different active substances. This list was then cross-referenced with selected antimicrobial prescribing guidelines provided by Intersectoral Society for Antibiotic Resistance Control (ISKRA), National Institute for Health and Care Excellence (NICE) and The Infectious Diseases Society of America (IDSA).ResultsSeven packages matched ISKRA guidelines on sore throat while 16 were mismatched. Considering drug packages under reimbursement, 3 matched ISKRA guidelines and 8 were mismatched. Only 3 packages matched IDSA guidelines for comparable indications, and 18 were mismatched. When considering NICE guidelines there were 5 mismatched and only one package that was in accordance with the guidelines. ISKRA guidelines for urinary tract infections matched 23 packages and mismatched 58 packages. IDSA guidelines for urinary tract infections matched one package and were mismatched in 15 cases.ConclusionsOne of the causes of leftover antibiotics is poor accordance of antibiotic package size with treatment recommendation duration. This should be identified as a potential target for reduction of excess antibiotics in the community. Measures that promote patient adherence to therapy and patient education should be considered essential to manage proper handling of leftover antibiotics.

Highlights

  • The aim of this study was to investigate whether marketed antibiotics package sizes are in accordance with treatment durations recommended in guidelines for prescribing antibiotics in sore throat and urinary tract infections

  • None of the matched drug packages were under reimbursement (Fig. 2)

  • There were 5 considered sore throat treatments proposed by Intersectoral Society for Antibiotic Resistance Control (ISKRA), 3 of which were matched

Read more

Summary

Introduction

The aim of this study was to investigate whether marketed antibiotics package sizes are in accordance with treatment durations recommended in guidelines for prescribing antibiotics in sore throat and urinary tract infections. Antibiotic resistance is recognized as a global threat to the health care system that may dramatically set back the modern medicine [1]. Various contributors to the emergence of antibiotic resistance have been identified. These include genetic factors intrinsic to bacteria, inappropriate antibiotic prescribing and sales, leftover antibiotics, use of antibiotics outside healthcare sector as well as the high. World Health Organization has released Global Action Plan on Antimicrobial Resistance which includes optimisation of the use of antimicrobial agents [5]. Global consumption of antibiotics is increasing [6]. Estimates are that in 2013 antibiotic usage in China was 162000 tons, 48% of which was human consumption [8]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call